{"id":348,"date":"1997-02-01T12:01:00","date_gmt":"1997-02-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1997\/postmenopausale-oestrogen-medikation-und-venoese-thromboembolien-myokardinfarkte-und-schlaganfaelle"},"modified":"1997-02-01T12:01:00","modified_gmt":"1997-02-01T11:01:00","slug":"postmenopausale-oestrogen-medikation-und-venoese-thromboembolien-myokardinfarkte-und-schlaganfaelle","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1997\/postmenopausale-oestrogen-medikation-und-venoese-thromboembolien-myokardinfarkte-und-schlaganfaelle","title":{"rendered":"Postmenopausale \u00d6strogen-Medikation und ven\u00f6se Thromboembolien, Myokardinfarkte und Schlaganf\u00e4lle"},"content":{"rendered":"<p>DER ARZNEIMITTELBRIEF hat in den letzten beiden Jahren mehrfach \u00fcber das ven\u00f6se Thromboembolierisiko bei Einnahme oraler Kontrazeptiva (AMB 1996, 30, 1 und 20) und \u00fcber Indikationen f\u00fcr die postmenopausale \u00d6strogen-&#8222;Substitution&#8220; (AMB 1995, 29, 45 und 65) berichtet. Die aktuelle Einnahme \u00f6strogenhaltiger oraler Kontrazeptiva (OK) ist ein eindeutiger Risikofaktor f\u00fcr die Entstehung ven\u00f6ser Thromboembolien bei jungen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DER ARZNEIMITTELBRIEF hat in den letzten beiden Jahren mehrfach \u00fcber das ven\u00f6se Thromboembolierisiko bei Einnahme oraler Kontrazeptiva (AMB 1996, 30, 1 und 20) und \u00fcber Indikationen f\u00fcr die postmenopausale \u00d6strogen-&#8222;Substitution&#8220; (AMB 1995, 29, 45 und 65) berichtet. Die aktuelle Einnahme \u00f6strogenhaltiger oraler Kontrazeptiva (OK) ist ein eindeutiger Risikofaktor f\u00fcr die Entstehung ven\u00f6ser Thromboembolien bei jungen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[58,60,61,59,57,71,63,68,64,67,69,65,70,62,66,56,53,54,51,55,52],"class_list":["post-348","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antikonzeptiva","tag-apoplektischer-insult","tag-beinvenenthrombose","tag-estrogene","tag-estrogene-gestagene","tag-herzinfarkt","tag-hirnblutung","tag-hirninfarkt","tag-kontrazeption","tag-kontrazeptiva","tag-lungenembolie","tag-myokardinfarkt","tag-osteoporose","tag-oestrogene","tag-oestrogene-gestagene","tag-schlaganfall","tag-subarachnoidalblutung","tag-thromboembolie","tag-thrombose","tag-venenthrombose","tag-verhuetung"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=348"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/348\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}